The CNMC has approved Boston Scientific Corporation's acquisition of B. Braun's EVT assets, which are used for gastrointestinal therapy. The transaction raised concerns about portfolio effects creating barriers to entry and expansion for competitors. BSC must adhere to commitments for five years, including not linking the sale of EVT products with other endoscopy devices and informing customers of these commitments. The affected industries are medical devices and healthcare. The legal areas involved are competition law and mergers. The main legal issues include portfolio effects and barriers to entry.